Non-adherence to IS therapy leading to graft rejection is well-recognized. We aim to study adherence to IS treatments and patient preferences in adolescent and adult liver recipients in a multi-ethnic Asian centre. Methods Liver recipients (age >18) on IS therapy on active follow up at our institution

were identified. An anonymous questionnaire form (available in English, Mandarin, this website Malay, Arabic) was given to each patient during a clinic visit (survey period Oct 2013 – Apr 2014). Completed forms were returned in unmarked sealed envelope. Results One hundred questionnaires were distributed; sixty-eight were returned fully completed and included in the present analysis. Based on the validated Morisky Adherence Score, only 5% of our cohort were considered to have “high adherence”; while 31% had “low adherence”. Liver recipients aged 20-39 were more likely to have low adherence compared to those between 40-69 years. Respondents were predominantly male (84%), with high school education (44%). Time from LT ranged

from <1 year to >10 years. 30% did not know the names of their current IS. 37% buy Forskolin admitted to missing IS doses; Tamoxifen research buy 7% missed doses once in 2 weeks; 12% missed doses once in 3 months. Evening doses were most commonly missed (18%). 57% felt once daily morning dosing regimen would improve IS adherence. Common reasons

for missed doses include “forgot” (19%), “too busy” (13%). 68% prefer to have their number of doses reduced and 28% found it difficult to take their evening dose on time. Patient’s ethnicity and primary language used, education level, occupation status, number of IS agents and amount spent on IS were not associated with adherence. Conclusion Adherence to immunosuppression is often under-reported by liver recipients. Extra vigilance and patient education by the transplant team is needed to improve adherence among younger liver recipients (20-39 years). Simplified immunosuppression dosing regimens with once daily regimens and a reduced pill burden may improve adherence to immunosuppressive therapy. Disclosures: Kieron B.